Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single‐centre experience

Abstract

Extracorporeal photopheresis as part of a multimodality approach yields a high durable clinical response in patients with erythrodremic MF and SS. The kinetics of the response differ between the blood and skin. The blood response occurs earlier and lasts longer; it does not necessarily predict the clinical skin response. Further studies are needed to determine if there is a survival advantage to a blood response in the absence of a skin response.

Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis

“…Owing to prior, life-threatening infectious complications in our patient, and a putative risk of neutropaenia under brentuximab vedotin, an add-on therapy with non-immunosuppressive ECP was chosen for CD30-negative non-responsive manifestations. Several topical or systemic combination modalities have been evaluated in conjunction with ECP, with additional therapeutic success (16). However, to date, there are no reports on such a multimodal approach combining ECP with brentuximab vedotin for SS and, altogether, only a few patients with SS have been reported to be treated successfully with brentuximab vedotin monotherapy.…”

Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T‐cell lymphoma

“…56 Positive responses were also observed when ECP was used in combination with various adjunctive therapies (e.g., IFN-α, phototherapy, steroids, alkylating agents). 57 ECP with IFN and/or retinoid therapy has led to high response rates in small studies of patients with SS. 58 As patients move through treatment regimens and continue to relapse, allogeneic hematopoietic stem cell transplantation (aHSCT) is considered for select patients.…”

Extracorporeal photopheresis and multimodality therapy in patients with T‐cell cutaneous lymphomas: Real‐life experience in Argentina

“…To date, the study of Atzmony et al 16 was the only one that described cutaneous and blood responses in patients with SS and erythrodermic MF, and their results were assessed in terms of cutaneous CR, PR, and SD, obtaining 30% CR, 35% PR, and 38.5% SD. These parameters are not similar enough to be matched with the ones in this study.…”

“…In this study, patients with MF and SS were not differentiated; for this reason, and to add new evidence for controlling this severe illness, we found it important to perform this study by evaluating skin and blood response rates separately. 16 The main objective of the present study was to assess cutaneous and peripheral blood responses in patients with MF and SS who received multimodality treatment including ECP. As a secondary objective, we evaluated pruritus and lactate dehydrogenase (LDH) values before and after multimodality treatment with ECP.…”